Significant off-target adverse events from novel treatments directed at molecular targets in CRPC

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses significant off-target adverse events from novel treatments directed at molecular targets in CRPC at ASCO GU 2016